CRPC
CRPC
Metastatic castration-resistant prostate cancer
Advertisement
Katy MarshallRLT | February 14, 2024
A total of 488 patients received an average of 2 cycles of 225Ac-PSMA RLT between January 2016 and May 2023.
Read More
Katy MarshallCRPC | February 13, 2024
Patients had previously received an androgen blockade with bicalutamide and an alternative AAT with flutamide.
Emily MenendezASCO GU Symposium 2024 | January 27, 2024
The study analyzed VISION-eligible patients with mCRPC who were classified as TheraP-eligible or ineligible.
Emily MenendezASCO GU Symposium 2024 | January 27, 2024
The study is the first large-scale report of patients in the United States treated with 177Lu-PSMA-617.
Pedro Barata, MDASCO GU Symposium 2024 | January 30, 2024
Drs. Barata and Wallis discuss the interaction of age and benefit of treatment intensification in advanced prostate cancer.
Brad McGregor, MDASCO GU Symposium 2024 | January 30, 2024
Drs. McGregor and Wallis highlight CONTACT-2, the first study of an ICI-based regimen to show improvement in rPFS in PC.
Emily MenendezASCO GU Symposium 2024 | January 26, 2024
HRQoL was maintained in the niraparib plus AAP arm, and patients experienced minimal side effect bother from treatment.
Katy MarshallASCO GU Symposium 2024 | January 26, 2024
The enzalutamide group experienced a significant deterioration in mean fatigue changes when compared with the AA group.
Christopher Wallis, MD, PhD, FRCSCASCO GU Symposium 2024 | January 25, 2024
Dr. Maha Hussain presented results of the BRCAAway trial in patients with mCRPC who have HRR mutations.
Zachary BessetteASCO GU Symposium 2024 | January 24, 2024
Cabozantinib plus atezolizumab improves rPFS versus second NHT in patients who had progressed on a prior NHT and have mCRPC.
Emily MenendezCRPC | January 10, 2024
There has been renewed interest in the platinum-based treatment of metastatic castration-resistant prostate cancer.
Katy MarshallmCSPC | December 29, 2023
Researchers noted a lack of research surrounding treatment-related adverse events in these patients.
John Shen, MDmCSPC | December 19, 2023
Drs. Shen and Graff discuss patient outcomes from TITAN and SPARTAN, as well as assessing functional vs chronological age.
Emily MenendezRLT | December 14, 2023
PSA levels were decreased by half in 46.9% of patients, and a decline in CTC count occurred 59.1% of patients.
Zachary BessetteCRPC | December 6, 2023
ASCO has provided a rapid update on its guideline recommendations for 177Lutetium-PSMA-617 in mCRPC.
Oliver Sartor, MDRLT | December 4, 2023
Drs. Wallis and Sartor highlight issues with the control arm and considerations for treatment sequencing related to PSMAfore.
Oliver Sartor, MDRLT | December 4, 2023
Dr. Sartor explains in detail the design and methodology, specific findings, nuances, and implications of the PSMAfore trial.
Zachary BessetteSUO 2023 | November 22, 2023
New research sheds light on the safety of (177Lu)–PSMA-617 for patients with mCRPC and poor bone marrow reserve.
Ravi A. Madan, MDCRPC | November 22, 2023
Dr. Madan describes the background for the PARPi approvals stemming from recent studies and the ongoing issues with them.
Emily MenendezCRPC | November 20, 2023
Compared with ADT alone, apalutamide plus ADT had a favorable hazard ratio across all end points regardless of age.
Advertisement
Advertisement
Advertisement